<?xml version='1.0' encoding='utf-8'?>
<document id="31650711"><sentence text="Evaluation of the Pharmacokinetic Interaction Between the Voltage- and Use-Dependent Nav1.7 Channel Blocker Vixotrigine and Carbamazepine in Healthy Volunteers."><entity charOffset="108-119" id="DDI-PubMed.31650711.s1.e0" text="Vixotrigine" /><entity charOffset="124-137" id="DDI-PubMed.31650711.s1.e1" text="Carbamazepine" /><pair ddi="false" e1="DDI-PubMed.31650711.s1.e0" e2="DDI-PubMed.31650711.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s1.e0" e2="DDI-PubMed.31650711.s1.e1" /></sentence><sentence text="Vixotrigine is a voltage- and use-dependent Nav1"><entity charOffset="0-11" id="DDI-PubMed.31650711.s2.e0" text="Vixotrigine" /></sentence><sentence text="7 channel blocker under investigation for the treatment of peripheral neuropathic pain conditions, including trigeminal neuralgia" /><sentence text=" Vixotrigine is metabolized primarily via uridine diphosphate-glucuronosyltransferases (UGTs)"><entity charOffset="1-12" id="DDI-PubMed.31650711.s4.e0" text="Vixotrigine" /><entity charOffset="42-61" id="DDI-PubMed.31650711.s4.e1" text="uridine diphosphate" /><pair ddi="false" e1="DDI-PubMed.31650711.s4.e0" e2="DDI-PubMed.31650711.s4.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s4.e0" e2="DDI-PubMed.31650711.s4.e1" /></sentence><sentence text=" Carbamazepine, a UGT and cytochrome P450 3A4 inducer, is a first-line treatment for trigeminal neuralgia"><entity charOffset="1-14" id="DDI-PubMed.31650711.s5.e0" text="Carbamazepine" /></sentence><sentence text=" We conducted a double-blind, randomized, placebo-controlled, parallel-group, single-center phase 1 study to investigate the impact of coadministering vixotrigine and carbamazepine on their respective pharmacokinetics (PK) in healthy volunteers, the safety and tolerability of combined treatment, and PK recovery of vixotrigine following carbamazepine discontinuation"><entity charOffset="151-162" id="DDI-PubMed.31650711.s6.e0" text="vixotrigine" /><entity charOffset="167-180" id="DDI-PubMed.31650711.s6.e1" text="carbamazepine" /><entity charOffset="316-327" id="DDI-PubMed.31650711.s6.e2" text="vixotrigine" /><entity charOffset="338-351" id="DDI-PubMed.31650711.s6.e3" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e0" e2="DDI-PubMed.31650711.s6.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e0" e2="DDI-PubMed.31650711.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e0" e2="DDI-PubMed.31650711.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e0" e2="DDI-PubMed.31650711.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e1" e2="DDI-PubMed.31650711.s6.e1" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e1" e2="DDI-PubMed.31650711.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e1" e2="DDI-PubMed.31650711.s6.e3" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e2" e2="DDI-PubMed.31650711.s6.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s6.e2" e2="DDI-PubMed.31650711.s6.e3" /></sentence><sentence text=" Randomly assigned treatments were carbamazepine (100 mg twice a day, days 1-3 and 200 mg twice a day, days 4-21) or placebo on days 1 to 21"><entity charOffset="35-48" id="DDI-PubMed.31650711.s7.e0" text="carbamazepine" /></sentence><sentence text=" All volunteers received vixotrigine 150 mg 3 times a day on days 16 to 28"><entity charOffset="25-36" id="DDI-PubMed.31650711.s8.e0" text="vixotrigine" /></sentence><sentence text=" At prespecified times, whole-blood samples were collected for PK assessment" /><sentence text=" Statistical analyses were performed on the log-transformed PK parameters area under the concentration-time curve within a dosing interval (AUC0-tau ) and maximum observed concentration (Cmax ) for vixotrigine, carbamazepine, and metabolites"><entity charOffset="198-209" id="DDI-PubMed.31650711.s10.e0" text="vixotrigine" /><entity charOffset="211-224" id="DDI-PubMed.31650711.s10.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.31650711.s10.e0" e2="DDI-PubMed.31650711.s10.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s10.e0" e2="DDI-PubMed.31650711.s10.e1" /></sentence><sentence text=" Vixotrigine AUC0-tau and Cmax were reduced by 31"><entity charOffset="1-12" id="DDI-PubMed.31650711.s11.e0" text="Vixotrigine" /></sentence><sentence text="6% and 26" /><sentence text="3%, respectively, when coadministered with carbamazepine compared with placebo"><entity charOffset="43-56" id="DDI-PubMed.31650711.s13.e0" text="carbamazepine" /></sentence><sentence text=" Seven days after carbamazepine discontinuation, vixotrigine AUC0-tau and Cmax remained 24"><entity charOffset="18-31" id="DDI-PubMed.31650711.s14.e0" text="carbamazepine" /><entity charOffset="49-60" id="DDI-PubMed.31650711.s14.e1" text="vixotrigine" /><pair ddi="false" e1="DDI-PubMed.31650711.s14.e0" e2="DDI-PubMed.31650711.s14.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s14.e0" e2="DDI-PubMed.31650711.s14.e1" /></sentence><sentence text="5% and 21" /><sentence text="4% lower compared with placebo" /><sentence text=" Carbamazepine AUC0-tau and Cmax were &lt;10% lower when coadministered with vixotrigine compared on days 15 and 21"><entity charOffset="1-14" id="DDI-PubMed.31650711.s17.e0" text="Carbamazepine" /><entity charOffset="74-85" id="DDI-PubMed.31650711.s17.e1" text="vixotrigine" /><pair ddi="false" e1="DDI-PubMed.31650711.s17.e0" e2="DDI-PubMed.31650711.s17.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s17.e0" e2="DDI-PubMed.31650711.s17.e1" /></sentence><sentence text=" Vixotrigine/carbamazepine coadministration was well tolerated"><entity charOffset="1-12" id="DDI-PubMed.31650711.s18.e0" text="Vixotrigine" /><entity charOffset="13-26" id="DDI-PubMed.31650711.s18.e1" text="carbamazepine" /><pair ddi="false" e1="DDI-PubMed.31650711.s18.e0" e2="DDI-PubMed.31650711.s18.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s18.e0" e2="DDI-PubMed.31650711.s18.e1" /></sentence><sentence text=" These results suggest that vixotrigine does not have an effect on carbamazepine PK, and although carbamazepine has an effect on the exposure of vixotrigine, the effect is not considered clinically relevant"><entity charOffset="28-39" id="DDI-PubMed.31650711.s19.e0" text="vixotrigine" /><entity charOffset="67-83" id="DDI-PubMed.31650711.s19.e1" text="carbamazepine PK" /><entity charOffset="98-111" id="DDI-PubMed.31650711.s19.e2" text="carbamazepine" /><entity charOffset="145-156" id="DDI-PubMed.31650711.s19.e3" text="vixotrigine" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e0" e2="DDI-PubMed.31650711.s19.e0" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e0" e2="DDI-PubMed.31650711.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e0" e2="DDI-PubMed.31650711.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e0" e2="DDI-PubMed.31650711.s19.e3" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e1" e2="DDI-PubMed.31650711.s19.e1" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e1" e2="DDI-PubMed.31650711.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e1" e2="DDI-PubMed.31650711.s19.e3" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e2" e2="DDI-PubMed.31650711.s19.e2" /><pair ddi="false" e1="DDI-PubMed.31650711.s19.e2" e2="DDI-PubMed.31650711.s19.e3" /></sentence><sentence text="" /></document>